CN112639467A - 血小板模拟粒子及其制备方法以及含该模拟粒子的质控物或校准物 - Google Patents
血小板模拟粒子及其制备方法以及含该模拟粒子的质控物或校准物 Download PDFInfo
- Publication number
- CN112639467A CN112639467A CN201880097228.3A CN201880097228A CN112639467A CN 112639467 A CN112639467 A CN 112639467A CN 201880097228 A CN201880097228 A CN 201880097228A CN 112639467 A CN112639467 A CN 112639467A
- Authority
- CN
- China
- Prior art keywords
- platelet
- particles
- animal
- red blood
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 167
- 238000003908 quality control method Methods 0.000 title claims abstract description 20
- 239000000126 substance Substances 0.000 title claims description 17
- 238000004088 simulation Methods 0.000 title abstract description 20
- 238000002360 preparation method Methods 0.000 title description 25
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 115
- 241001465754 Metazoa Species 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 46
- 150000001299 aldehydes Chemical class 0.000 claims abstract description 39
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 33
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 33
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 33
- 229940033123 tannic acid Drugs 0.000 claims abstract description 33
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 33
- 229920002258 tannic acid Polymers 0.000 claims abstract description 33
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 30
- 230000004048 modification Effects 0.000 claims abstract description 26
- 238000012986 modification Methods 0.000 claims abstract description 26
- -1 trifluoromethyl compound Chemical class 0.000 claims abstract description 15
- 230000027455 binding Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 210000001772 blood platelet Anatomy 0.000 claims description 41
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 30
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 claims description 19
- 241000283707 Capra Species 0.000 claims description 18
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- DLRCWXOCZIUZBS-UHFFFAOYSA-N 2,4-bis(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C(C(F)(F)F)=C1 DLRCWXOCZIUZBS-UHFFFAOYSA-N 0.000 claims description 9
- SWKPKONEIZGROQ-UHFFFAOYSA-N 4-trifluoromethylbenzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000834 fixative Substances 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 claims description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 5
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 229940118019 malondialdehyde Drugs 0.000 claims description 5
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 5
- 229920002866 paraformaldehyde Polymers 0.000 claims description 5
- JVTSHOJDBRTPHD-UHFFFAOYSA-N 2,2,2-trifluoroacetaldehyde Chemical compound FC(F)(F)C=O JVTSHOJDBRTPHD-UHFFFAOYSA-N 0.000 claims description 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 4
- 229920001864 tannin Polymers 0.000 claims description 4
- 235000018553 tannin Nutrition 0.000 claims description 4
- 239000001648 tannin Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 238000004043 dyeing Methods 0.000 claims description 3
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 42
- 210000000601 blood cell Anatomy 0.000 description 38
- 238000005406 washing Methods 0.000 description 27
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 19
- 239000001509 sodium citrate Substances 0.000 description 18
- 239000007853 buffer solution Substances 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 210000000265 leukocyte Anatomy 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 210000001995 reticulocyte Anatomy 0.000 description 12
- 239000000725 suspension Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003219 hemolytic agent Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
一种制备血小板模拟粒子的方法，其中使用三氟甲基类化合物对动物红细胞进行修饰处理，以制成能结合荧光染料的血小板模拟粒子。该方法能使血小板模拟粒子与荧光染料分子简单、有效地结合。还涉及另一种制备血小板模拟粒子的方法，其中使用单宁酸和醛类对动物红细胞进行固定处理，以制成血小板模拟粒子。该方法能提高血小板模拟粒子的稳定性。此外还涉及按照该方法制备的血小板模拟粒子及含有该血小板模拟粒子的质控物或校准物。
Description
PCT国内申请，说明书已公开。
Claims (20)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/123638 WO2020132906A1 (zh) | 2018-12-25 | 2018-12-25 | 血小板模拟粒子及其制备方法以及含该模拟粒子的质控物或校准物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112639467A true CN112639467A (zh) | 2021-04-09 |
| CN112639467B CN112639467B (zh) | 2024-04-09 |
Family
ID=71127569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880097228.3A Active CN112639467B (zh) | 2018-12-25 | 2018-12-25 | 血小板模拟粒子及其制备方法以及含该模拟粒子的质控物或校准物 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112639467B (zh) |
| WO (1) | WO2020132906A1 (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075556A (en) * | 1989-12-01 | 1991-12-24 | Technicon Instruments Corporation | Acridine orange derivatives and their use in the quantitation of reticulocytes in whole blood |
| US5360739A (en) * | 1991-12-05 | 1994-11-01 | Miles Inc. | Methods for the identification and characterization of reticulocytes in whole blood |
| CN1096375A (zh) * | 1993-06-11 | 1994-12-14 | 上海市血液中心 | 血小板抗原抗体反应的指示试剂、其制备方法及其用途 |
| CN101273995A (zh) * | 2007-03-30 | 2008-10-01 | 陕西北美基因股份有限公司 | 吩噻嗪类染料修饰的磁性微粒的制备方法和用途 |
| CN102109430A (zh) * | 2009-12-25 | 2011-06-29 | 深圳迈瑞生物医疗电子股份有限公司 | 有核红细胞模拟粒子，血液质控物及其制备方法和用途 |
| CN102317458A (zh) * | 2008-12-04 | 2012-01-11 | 欧科库尔纳有限责任公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
| CN103454410A (zh) * | 2012-05-30 | 2013-12-18 | 桂林优利特医疗电子有限公司 | 血液测试仪用生物安全质控物及其制备方法 |
| CN104977284A (zh) * | 2015-07-03 | 2015-10-14 | 石莹 | 一种胎儿有核红细胞的捕获及鉴定方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179398A (en) * | 1977-03-21 | 1979-12-18 | ICN Medical Laboratories, Inc. | Platelet control composition |
| US5008201A (en) * | 1990-05-24 | 1991-04-16 | Streck Laboratories, Inc. | Simulated human platelets from red blood cells |
| CN1891230A (zh) * | 2005-07-04 | 2007-01-10 | 深圳迈瑞生物医疗电子股份有限公司 | 血小板模拟物及其制备方法 |
-
2018
- 2018-12-25 WO PCT/CN2018/123638 patent/WO2020132906A1/zh active Application Filing
- 2018-12-25 CN CN201880097228.3A patent/CN112639467B/zh active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075556A (en) * | 1989-12-01 | 1991-12-24 | Technicon Instruments Corporation | Acridine orange derivatives and their use in the quantitation of reticulocytes in whole blood |
| US5360739A (en) * | 1991-12-05 | 1994-11-01 | Miles Inc. | Methods for the identification and characterization of reticulocytes in whole blood |
| CN1096375A (zh) * | 1993-06-11 | 1994-12-14 | 上海市血液中心 | 血小板抗原抗体反应的指示试剂、其制备方法及其用途 |
| CN101273995A (zh) * | 2007-03-30 | 2008-10-01 | 陕西北美基因股份有限公司 | 吩噻嗪类染料修饰的磁性微粒的制备方法和用途 |
| CN102317458A (zh) * | 2008-12-04 | 2012-01-11 | 欧科库尔纳有限责任公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
| CN102109430A (zh) * | 2009-12-25 | 2011-06-29 | 深圳迈瑞生物医疗电子股份有限公司 | 有核红细胞模拟粒子，血液质控物及其制备方法和用途 |
| CN103454410A (zh) * | 2012-05-30 | 2013-12-18 | 桂林优利特医疗电子有限公司 | 血液测试仪用生物安全质控物及其制备方法 |
| CN104977284A (zh) * | 2015-07-03 | 2015-10-14 | 石莹 | 一种胎儿有核红细胞的捕获及鉴定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020132906A1 (zh) | 2020-07-02 |
| CN112639467B (zh) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3391451B2 (ja) | 白血球類縁体用の血液対照組成物，およびその調製方法および使用方法 | |
| JP4549440B2 (ja) | 基準対照血液および製法 | |
| JP4993603B2 (ja) | 有核赤血球成分を含む参照対照 | |
| EP0305491B1 (en) | System for isolating and identifying leukocytes | |
| JP4999681B2 (ja) | 未成熟の顆粒球成分を含む血液学の参照対照 | |
| JP4042925B2 (ja) | 幼若白血球の分類計数法 | |
| US9995736B2 (en) | Preparation and use of nucleated red blood cell simulating particles and hematology control mixtures | |
| US7592179B2 (en) | Five-part differential white blood cell control and method for preparation of the same | |
| JPH07504035A (ja) | 血液組成物用懸濁媒体及びその使用方法 | |
| US8383403B2 (en) | Reticulocyte mimetics and method of preparation of the same | |
| US6653137B2 (en) | Hematology reference control | |
| US6723563B2 (en) | Hematology reference control | |
| CN105717312B (zh) | 一种红细胞模拟粒子、其制备方法以及含该模拟粒子的质控物或校准物 | |
| JPH0726955B2 (ja) | 保存全血試料の調製方法 | |
| CN112305232A (zh) | 血液与特定蛋白的混合质控物及其质控方法 | |
| CN110987553B (zh) | 一种红细胞处理试剂及其应用 | |
| WO2013019290A9 (en) | Immature reticulocyte fraction reference control and related methods | |
| US6146901A (en) | Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition | |
| CN112639467B (zh) | 血小板模拟粒子及其制备方法以及含该模拟粒子的质控物或校准物 | |
| JP2007515623A (ja) | 有核赤血球の測定のためのリファレンスコントロールの使用方法 | |
| US20090035758A1 (en) | Method of Measurement of Micronucleated Erythrocyte Populations | |
| WO2004003568A1 (en) | Hematology reference control | |
| CN114196666B (zh) | 一种网织红细胞模拟物及其制备方法、网织红细胞质控物 | |
| WO2018126499A1 (zh) | 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 | |
| JP3631203B2 (ja) | 溶血性貧血検査方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |